RSS

Cx601

The first allogenic stem cell therapy — Alofisel (darvadstrocel) from TiGenix and Takeda Pharmaceutical Company — has received marketing authorisation approval from the EC for the treatment of complex perianal fistulas in Crohn’s disease more

News

Takeda Pharmaceutical Company has announced its intention to acquire the advanced biopharmaceutical company, TiGenix. more

News

Biopharmaceutical company, TiGenix, has submitted responses to the marketing authorisation application for Cx601, a treatment of complex perianal fistulas in Crohn’s disease patients as a first indication. more

News